The study will assess the efficacy and safety of zorevunersen compared to sham over a 52-week treatment period.

Stoke Therapeutics, Inc. (Nasdaq: STOK) is a biotechnology company dedicated to restoring protein expression by harnessing the body’s potential with RNA medicine and has a lead investigational ...

Stoke Therapeutics ( ($STOK) ) has released its Q2 earnings. Here is a breakdown of the information Stoke Therapeutics presented to its investors.

The Brennan family will host the 7th Annual Dance for Dravet on September 26th at the Third Degree Glass Factory to raise ...

The global Phase III EMPEROR trial (NCT06872125) will evaluate the safety and efficacy of zorevunersen, a novel antisense ...

Global, pivotal Phase 3 study will evaluate efficacy and safety of zorevunersen compared to sham over a 52-week treatment period - ...

Dravet syndrome is difficult to treat and has a poor long-term prognosis. Complications of the disease often contribute to a poor quality of life for patients and their caregivers.

Dravet syndrome, a rare and severe form of epilepsy, presents significant challenges for patients, families, and caregivers, including multiple seizures per day and substantial developmental ...

As heatwaves become more intense with climate change, scientists are racing to understand how extreme heat changes the way ...

Therefore, Dravet syndrome can create severe adverse impacts on your child’s life. But now you can help them to get relief from the intense health issues resulting from this disorder with the ...

"Dravet Syndrome, seizures and what goes along with it usually changes every year," Nicole Watson said. Because it's so rare, research and treatments are limited and Nicole Watson is working to ...

"Dravet syndrome affects 1 in 14,000 children in the world and has a profound impact on children and their families," said Ethan Goldberg, MD, PhD, a pediatric neurologist and Director of the ...